4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Clal Biotechnology Industries Ltd. (CBI) operates in the Biotechnology industry and is headquartered in Tel Aviv, Israel. Its market capitalization is roughly ₪38 million. In the fiscal year ended 2025-12-31, CBI reported ₪0M in revenue and (₪13M) in net income.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | ₪0M | ₪0M | ₪0M | ₪0M | — |
| Gross Profit | — | — | — | — | ₪11M |
| Operating Income (EBIT) | (₪5M) | (₪7M) | (₪10M) | (₪12M) | — |
| Net Income | (₪13M) | (₪62M) | (₪31M) | (₪62M) | — |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | — | — | — | — | (₪36M) |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | ₪42M | ₪68M | ₪158M | ₪183M | — |
| Total Liabilities | ₪19M | ₪22M | ₪37M | ₪38M | — |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CBI viewer.
This page in other languages: עברית
About TickerBase · Data methodology & sources · Privacy · Terms